Last reviewed · How we verify

Intec Pharma Ltd. — Portfolio Competitive Intelligence Brief

Intec Pharma Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo -AP-CD/LD Placebo -AP-CD/LD phase 3
Placebo- Sinemet Placebo- Sinemet phase 3 Dopamine agonist Dopamine receptors Neurology
Accordion Pill™ Carbidopa/Levodopa Accordion Pill™ Carbidopa/Levodopa phase 3 Dopamine precursor with peripheral decarboxylase inhibitor Aromatic L-amino acid decarboxylase (carbidopa); dopamine pathway (levodopa) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Axxonis Pharma AG · 1 shared drug class
  2. Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
  3. Beth Israel Deaconess Medical Center · 1 shared drug class
  4. Bial - Portela C S.A. · 1 shared drug class
  5. Britannia Pharmaceuticals Ltd. · 1 shared drug class
  6. Desitin Arzneimittel GmbH · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Intec Pharma Ltd.:

Cite this brief

Drug Landscape (2026). Intec Pharma Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/intec-pharma-ltd. Accessed 2026-05-14.

Related